KEGG   DRUG: Insulin glargine
Entry
D03250                      Drug                                   
Name
Insulin glargine (USAN/INN);
Insulin glargine (genetical recombination) (JP18);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN);
Lantus (TN)
Product
Formula
C267H404N72O78S6
Exact mass
6058.8184
Mol weight
6062.8903
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Gly
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
Arg Arg
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01797  Insulin analog, long-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AE04
Product: D03250<JP/US>
Product (mixture): D11034<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE04 Insulin glargine
      D03250  Insulin glargine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Glargine
     D03250  Insulin glargine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D03250  Insulin glargine (USAN/INN); Insulin glargine (genetical recombination) (JP18); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01797  Insulin analog, long-acting
    D03250  Insulin glargine
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D03250  Insulin glargine
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D03250  Insulin glargine
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D03250  Insulin glargine (USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D03250  Insulin glargine (genetical recombination)
  D03250  Insulin glargine (genetical recombination) injection
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03250
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03250
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03250
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03250
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D03250
Other DBs
CAS: 160337-95-1
PubChem: 17397403
NIKKAJI: J2.173.686D
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system